Search Results | OpenEmory

Start Over Keyword CD33

Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia

Authors:Bhavani Gopalakrishnan, Ohio State UniversityCarolyn Cheney, Ohio State UniversityRajeswaran Mani, Ohio State UniversityXiaokui Mo, Ohio State UniversityDonna Bucci, Ohio State UniversityAlison Walker, Ohio State UniversityRebecca Klisovic, Emory UniversityBhavana Bhatnagar, Ohio State UniversityKatherine Walsh, Ohio State UniversityBjoern Rueter, Boehringer Ingelheim Pharma GmbH, Biberach/RissIrene C. Waizenegger, Boehringer Ingelheim Pharma GmbH, Biberach/RissKarl-Heinz Heider, Boehringer Ingelheim Pharma GmbH, Biberach/RissWilliam Blum, Emory UniversitySumithira Vasu, Ohio State UniversityNatarajan Muthusamy, Ohio State University

Date:2018

Publisher:Impact Journals

Publication Version:Final Published Version

License:Creative Commons Attribution 3.0 Unported